Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy MAIA Biotechnology stock in Canada

MAIA Biotechnology stock has moved -0.62% from yesterday's closing price. Learn how to easily invest in MAIA Biotechnology stock.

MAIA Biotechnology is a biotechnology business based in the US. MAIA Biotechnology stocks (MAIA.US) are listed on the NYSE MKT and all prices are listed in US Dollars. Its last market close was $3.3205 – an increase of 2.17% over the previous week. MAIA Biotechnology employs 9 staff and has a market cap (total outstanding stock value) of $36.1 million.

How to buy stocks in MAIA Biotechnology

  1. Compare stock trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – MAIA – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of stocks with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

MAIA Biotechnology stock price (NYSE MKT:MAIA)

Use our graph to track the performance of MAIA stocks over time.

MAIA Biotechnology shares at a glance

Information last updated 2022-09-21.
Latest market close$3.32
52-week range$3.26 - $9.64
50-day moving average $4.41
200-day moving average $4.41
Wall St. target priceN/A
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) N/A

Compare stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

1 - 5 of 5
Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
OFFER
CIBC Investor's Edge
Finder Rating:
★★★★★
4 / 5
$4.95–$6.95
$0 if conditions met, else $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Young investors 18 to 24 can get free online trades and a $0 annual account fee. Conditions apply.
Interactive Brokers
Finder Rating:
★★★★★
4.1 / 5
min $1.00, max 0.5%
$0
Stocks, Bonds, Options, ETFs, Currencies, Futures
Questrade
Finder Rating:
★★★★★
4.2 / 5
$4.95 - $9.95
$0
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
FREE TRADES
Wealthsimple
Finder Rating:
★★★★★
3.9 / 5
$0
$0
Stocks, ETFs
Get $25 when you open a Wealthsimple account and fund at least $150.
OFFER
Qtrade Direct Investing
Finder Rating:
★★★★★
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get almost $500 in commission free trades when you fund your new account with a minimum of $10,000. Conditions apply. Ends October 31, 2022.
loading

Compare up to 4 providers

Is it a good time to buy MAIA Biotechnology stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

MAIA Biotechnology price performance over time

Historical closes compared with the close of $3.3205 from 2022-09-29

1 week (2022-09-23) 2.17%
1 month (2022-09-01) -19.83%
3 months (2022-06-27) N/A
6 months (2022-03-28) N/A
1 year (2021-09-27) N/A
2 years (2020-09-27) N/A
3 years (2019-09-27) N/A
5 years (2017-09-27) N/A

MAIA Biotechnology financials

Gross profit TTM $0
Return on assets TTM 0%
Return on equity TTM 0%
Profit margin 0%
Book value $0.79
Market capitalisation $36.1 million

TTM: trailing 12 months

MAIA Biotechnology share dividends

We're not expecting MAIA Biotechnology to pay a dividend over the next 12 months.

MAIA Biotechnology overview

MAIA Biotechnology, Inc. , a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer, primarily non-small cell lung cancer. Its lead asset, THIO, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The company was founded in 2018 and is headquartered in Chicago, Illinois. .

Frequently asked questions


Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site